BridgeBio Pharma, Inc. (BIT:1BBIO)

Italy flag Italy · Delayed Price · Currency is EUR
33.96
+0.01 (0.03%)
At close: May 2, 2025
Market Cap 6.46B
Revenue (ttm) 117.88M
Net Income (ttm) -618.00M
Shares Out n/a
EPS (ttm) -3.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 40
Open n/a
Previous Close 33.95
Day's Range n/a
52-Week Range 32.89 - 34.42
Beta n/a
RSI n/a
Earnings Date Aug 1, 2025

About BridgeBio Pharma

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for t... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 730
Stock Exchange Borsa Italiana
Ticker Symbol 1BBIO
Full Company Profile

Financial Performance

In 2024, BridgeBio Pharma's revenue was $221.90 million, an increase of 2285.27% compared to the previous year's $9.30 million. Losses were -$535.76 million, -16.70% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.